Ryaltris US Debut Plan, Generic Spiriva Fuel Buoyant Glenmark Outlook
Also Strikes Deal With AZ For Pulmicort Respules In Colombia
Glenmark makes buoyant sales projections for Ryaltris, which is set for US debut in the first quarter of FY23 and has also seen launch momentum in several international markets. The rhinitis therapy along with generic Spiriva are seen as pivotal to drive the Indian company's growth in Europe.
